Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study

BACKGROUND: Since breast cancer is less common in men than in women, data on the use of new therapeutic agents, including cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors, are limited in patients with metastatic hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2...

Descripción completa

Detalles Bibliográficos
Autores principales: Yıldırım, Hasan Çağrı, Mutlu, Emel, Chalabiyev, Elvin, Özen, Miraç, Keskinkılıç, Merve, Ön, Sercan, Çelebi, Abdussamet, Dursun, Bengü, Acar, Ömer, Kahraman, Seda, Aykan, Musa Barış, Kaman, Ömür, Doğan, Akif, Erdoğan, Atike Pınar, Melisa Celayir, Özde, Günenç, Damla, Güven, Deniz Can, Vedat Bayoğlu, İbrahim, Yavuzşen, Tuğba, Hacıbekiroğlu, İlhan, İnanç, Mevlüde, Kılıçkap, Saadettin, Yalçın, Şuayib, Aksoy, Sercan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547301/
https://www.ncbi.nlm.nih.gov/pubmed/36208540
http://dx.doi.org/10.1016/j.breast.2022.09.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547301/
https://www.ncbi.nlm.nih.gov/pubmed/36208540
http://dx.doi.org/10.1016/j.breast.2022.09.009

Ejemplares similares